Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy

Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy

Aim: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). Materials & methods: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences...

Full description

Bibliographic Details
Main Authors: Michele Dionese, Umberto Basso, Francesco Pierantoni, Eleonora Lai, Nicolò Cavasin, Elisa Erbetta, Salim Jubran, Giorgio Bonomi, Davide Bimbatti, Marco Maruzzo
Format: Article
Language:English
Published: Taylor & Francis Group 2023-08-01
Series:Future Science OA
Subjects:
bladder carcinoma
immune-related adverse events
immunotherapy
neutrophil-to-lymphocyte ratio
urothelial carcinoma
Online Access:https://www.future-science.com/doi/10.2144/fsoa-2023-0049
Description
Summary:Aim: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). Materials & methods: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values. Results: neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS. Conclusion: baseline inflammatory indexes are prognostic for mUC patients treated with ICIs.
ISSN:2056-5623

Similar Items